SG11202000347UA - A composition for treating and/or preventing hepatitis b virus infection and the use thereof - Google Patents

A composition for treating and/or preventing hepatitis b virus infection and the use thereof

Info

Publication number
SG11202000347UA
SG11202000347UA SG11202000347UA SG11202000347UA SG11202000347UA SG 11202000347U A SG11202000347U A SG 11202000347UA SG 11202000347U A SG11202000347U A SG 11202000347UA SG 11202000347U A SG11202000347U A SG 11202000347UA SG 11202000347U A SG11202000347U A SG 11202000347UA
Authority
SG
Singapore
Prior art keywords
treating
composition
virus infection
preventing hepatitis
hepatitis
Prior art date
Application number
SG11202000347UA
Inventor
Yi Zhang
Original Assignee
Yisheng Biopharma Singapore Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yisheng Biopharma Singapore Pte Ltd filed Critical Yisheng Biopharma Singapore Pte Ltd
Publication of SG11202000347UA publication Critical patent/SG11202000347UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202000347UA 2017-08-10 2018-08-01 A composition for treating and/or preventing hepatitis b virus infection and the use thereof SG11202000347UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201706540X 2017-08-10
PCT/SG2018/050391 WO2019032046A1 (en) 2017-08-10 2018-08-01 A composition for treating and/or preventing hepatitis b virus infection and the use thereof

Publications (1)

Publication Number Publication Date
SG11202000347UA true SG11202000347UA (en) 2020-02-27

Family

ID=63524350

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000347UA SG11202000347UA (en) 2017-08-10 2018-08-01 A composition for treating and/or preventing hepatitis b virus infection and the use thereof

Country Status (14)

Country Link
US (2) US11135286B2 (en)
EP (1) EP3664840A1 (en)
KR (1) KR20200047524A (en)
CN (1) CN110944662A (en)
AU (1) AU2018313636A1 (en)
BR (1) BR112020002627A2 (en)
CA (1) CA3070935A1 (en)
CU (1) CU24699B1 (en)
MX (1) MX2020001226A (en)
MY (1) MY202256A (en)
PH (1) PH12020500176A1 (en)
RU (1) RU2020108205A (en)
SG (1) SG11202000347UA (en)
WO (1) WO2019032046A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230081039A1 (en) * 2020-05-29 2023-03-16 Beijing Yisheng Biotechnology Co., Ltd. Pharmaceutical composition comprising polynucleotides and use thereof for prevention or treatment of covid-19
CN111529516B (en) * 2020-06-04 2022-03-15 山东大学 Application of spermidine in preparation of anti-hepatitis B virus drugs
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23031A1 (en) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech SURFACE ANTIGEN OF THE HEPATITIS B VIRUS AS A MUCOSOPT IMMUNOPOTENTIATOR, RESULTS FORMULATIONS
AU2005332599B2 (en) * 2005-06-08 2012-02-16 Yisheng Biopharma (Singapore) Pte. Ltd. Polyinosinic acid-polycytidylic acid-based adjuvant
US7868159B2 (en) * 2005-06-23 2011-01-11 Baylor College Of Medicine Modulation of negative immune regulators and applications for immunotherapy
US20070166800A1 (en) 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
US20090136538A1 (en) 2006-05-22 2009-05-28 Jan Jezek Stable vaccine formulation
RU2477753C2 (en) * 2008-12-09 2013-03-20 Коули Фармасьютикал Груп, Инк. Immunostimulating oligonucleotides
US9480714B2 (en) 2012-11-13 2016-11-01 Allan Yang Wu Methods and systems for processing exosomes
CN106715431A (en) * 2014-09-16 2017-05-24 吉利德科学公司 Solid forms of a toll-like receptor modulator
SI3507276T1 (en) * 2016-09-02 2022-01-31 Gilead Sciences, Inc. Toll like receptor modulator compounds
JP7289265B2 (en) * 2016-10-26 2023-06-09 キュアバック エスイー Lipid nanoparticle mRNA vaccine
US11324820B2 (en) * 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection

Also Published As

Publication number Publication date
RU2020108205A (en) 2021-09-10
KR20200047524A (en) 2020-05-07
US20220211840A1 (en) 2022-07-07
CA3070935A1 (en) 2019-02-14
EP3664840A1 (en) 2020-06-17
CN110944662A (en) 2020-03-31
US11135286B2 (en) 2021-10-05
MX2020001226A (en) 2020-07-20
RU2020108205A3 (en) 2022-01-31
PH12020500176A1 (en) 2020-09-14
BR112020002627A2 (en) 2020-07-28
WO2019032046A1 (en) 2019-02-14
CU24699B1 (en) 2024-03-05
US11690909B2 (en) 2023-07-04
MY202256A (en) 2024-04-19
US20200222529A1 (en) 2020-07-16
CU20200009A7 (en) 2020-11-30
AU2018313636A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
HK1251219A1 (en) Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection
IL257384A (en) Rnai-containing compositions and use of same for treating hepatitis b virus infection
IL263558A (en) Papd5 and papd7 inhibitors for treating a hepatitis b infection
HK1223931A1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
MA45863A (en) ARNI AGENT AGAINST HEPATITIS B INFECTION
EP3325097A4 (en) Compositions and agents against hepatitis b virus and uses thereof
EP3653630A4 (en) Endocyclic thiamidinoamide-arylamide compound and use thereof for treating hepatitis b
PH12016501379A1 (en) Azepane derivatives and methods of treating hepatitis b infections
WO2016109684A3 (en) Derivatives and methods of treating hepatitis b infections
IL274298A (en) Amino-thaizole substituted indole-z-carboxamides and compositions comprising same for use against the hepatitis b virus (hbv)
IL263859A (en) Phosphoramidates for the treatment of hepatitis b virus
IL282881A (en) Methods for treating hepatitis b infection
SG11202000896VA (en) Bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders
SG11202000347UA (en) A composition for treating and/or preventing hepatitis b virus infection and the use thereof
EP3556402A4 (en) Pharmaceutical composition for preventing or treating hepatitis b
EP3463469C0 (en) Combination of ledipasvir and sofosbuvir for use in the treatment of hepatitis b virus infections in humans
ZA202104244B (en) Recombinant viruses and the uses thereof
IL277128A (en) Hepatitis b vaccines and uses of the same
IL266526A (en) Recombinant virus, composition comprising the same, and uses thereof
IL279078A (en) Combination therapy for treating hepatitis b virus infection
ZA202104076B (en) Hepatitis b virus vaccine and uses thereof
GB201808500D0 (en) Virus and virus use
SG11202101660PA (en) Composition for preventing infection with human immunodeficiency virus
EP3894402C0 (en) N-containing chromen-4-one derivatives for the treatment and prophylaxis of hepatitis b virus infection
GB201813175D0 (en) Virus use